Cancer Management and Research (Dec 2020)
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients
Abstract
Zhicheng Hu,1 Yanchao Rong,1 Shuting Li,2 Shanqiang Qu,3 Shaobin Huang4 1Burns Department, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China; 2Department of Plastic Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China; 3Section of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 4Department of Cosmetic and Plastic Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Shanqiang QuSection of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province 510515, People’s Republic of ChinaEmail [email protected] HuangDepartment of Cosmetic and Plastic Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province 510655, People’s Republic of ChinaEmail [email protected]: Melanoma is the most malignant tumor among skin tumors, and its morbidity and mortality are increasing year by year. Although melanoma biology has been increasingly studied, no prognostic biomarkers have yet been incorporated into clinical protocols. Histone deacetylase 6 (HDAC6) has been shown to act as a prognostic biomarker in several cancers. Here, we aimed to investigate the predictive value of HDAC6 for the prognosis of cutaneous melanoma patients.Methods: Eighty cutaneous melanoma patients were enrolled in this study. The protein and mRNA expression levels of HDAC6 were detected, and the clinical features and survival time of cutaneous melanoma patients with HDAC6 expression were analyzed.Results: The results suggested that high HDAC6 expression was significantly associated with unfavorable clinicopathological features. High HDAC6 expression was related to melanoma metastasis and was also associated with a reduced survival time in melanoma patients, and this association remained significant in multivariate analysis adjusted for all other factors.Conclusion: These findings validate the utility of HDAC6 expression as an independent biomarker for the prognostication of patients with cutaneous melanoma.Keywords: HDAC6, cutaneous melanoma, prognostic biomarker, survival, metastasis
